Table 6.
Infections in 76 patients treated with rituximab via the LP or RA protocols.
| Infection | Number of infections N=76 (%)§ |
Duration since last RTX | Concomitant therapies |
|---|---|---|---|
| Disseminated nocardiosis with widespread abscesses leading to death | 1 (1.3%) | 1 wk | pred |
| Pneumocystis jirovecii pneumonia | 1 (1.3%) | 6 m | psl, aza |
| Joint infection with septic shock | 1 (1.3%) | 2 wk | psl, aza |
| Osteomyelitis | 1 (1.3%) | 4 m | psl |
| Erysipelas | 2 (2.6%) | 3 wk, 10 wk | dap, aza |
| Staphylococcus aureus skin infection/impetigo | 3 (3.9%) | NR | pred, dap |
| Herpes Simplex | 1 (1.3%) | NR | NR |
| Upper respiratory tract infection | 1 (1.3%) | NR | NR |
| Herpes Zoster | 1 (1.3%) | 0 wk | mmf |
| COVID-19 pneumonia | 1 (1.3%) | 10 m*, 2 m** | pred |
| Viral conjunctivitis | 1 (1.3%) | NR | NR |
| Dental abscess | 1 (1.3%) | 4 m | psl, aza |
§ Clinical outcomes were not reported in five out of 81 patients treated with RTX via the RA or LP protocols.
*After initial rituximab.
**After repeat rituximab.
Psl, prednisolone; pred, prednisone; aza, azathioprine; mmf, mycophenolate mofetil; dap, dapsone; NR, not reported. *after initial rituximab, **after repeat rituximab.